Subscribe to our Newsletters !!
Eliminating sticker residue is a small yet frustra
Recent advances in precision science have abandone
The Nobel Prize in Physiology or Medicine awarded
Giesen, Germany. 26 January 2026 - At Interpack 20
Alembic Pharmaceuticals Limited (Alembic) today an
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micro
Britain’s GlaxoSmithKline and France’s Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate and aim to get to the final testing phase in the second quarter.
If the results are conclusive, both drugmakers hope to find the vaccine approved by the fourth quarter after having originally targeted the first half of this year.
The move comes after the drugmakers in December said their vaccine could be delayed after clinical trials showed an inadequate immune response in older people.
The new trial will aim at evaluating the safety, tolerability and immune response of the vaccine in 720 healthy adults across the United States, Honduras and Panama, the companies said.
Sanofi and GSK’s candidate utilizes the exact recombinant protein-based technology among Sanofi’s seasonal flu vaccines. It’ll be combined with an adjuvant, a substance that acts as a booster to the shot, made by GSK.
The study will examine two injections given 21 days apart.
